Avance Clinical on the Top Reasons APAC Biotech Clients Chose Australia for Clinical Trials
April 2, 2020
Leading Australian CRO Avance Clinical today detailed the top reasons its APAC biotechs selected Australia for their early phase clinical trials, based on client onboarding feedback. Avance Clinical is a specialist Australian CRO with more than 20-years of early phase clinical trials expertise. Avance Clinical said a primary reason that APAC biotechs chose Australia was […]
Leading Australian CRO Avance Clinical today detailed the top reasons its APAC biotechs selected Australia for their early phase clinical trials, based on client onboarding feedback.
Avance
Clinical is a specialist Australian CRO with more than 20-years of early phase
clinical trials expertise.
Avance Clinical said a primary reason
that APAC biotechs chose Australia was the attractive Australian Government
financial rebate of more than 40% on clinical trial spend.
The Avance Clinical executive team
Avance Clinical
CEO Yvonne Lungershausen said this makes good financial sense for biotechs in
early clinical phases.
Another key factor is that, during the current
COVID-19 pandemic, sites can pivot to patient video visits or telemedicine, which
this week got a Government funding boost as part of a AUD$1.1 billion COVID-19
package.
“This additional
funding into an already high-tech medical environment means sites are rapidly able
to incorporate telehealth visits to overcome challenges faced by patients not
wanting to visit clinics during the pandemic.”
“Australia’s
reputation for FDA compliant scientific and research excellence, its advanced
healthcare, and the opportunity to access patients in a less clinical trial
competitive environment further reinforces its advantage as a destination for clinical
trials.”
“Avance is the CRO
of choice for clinical trials – as well as those targeting COVID-19.”
The top reasons for selecting Australia
are:
The
Government R&D grant means more than 40% rebate on clinical trial
spend
Telehealth
pivot during COVID-19 pandemic – speed and continuity
Site
Initiation Visit (SIV) and Study Start achieved in 5 – 6
weeks
No IND
required for clinical trials
Full GMP material
is not mandated for Phase I clinical trials
Established
clinical trial environment with world-class Investigators and sites
Established
healthy subject databases and specialised patient populations
Five independent
Phase 1 facilities across Australia including hospital-based units for
critical care
Major
hospitals with world class infrastructures and dedicated Clinical Trial
Units with a long track-record in FDA compliant research
Seasonal
studies: Northern hemisphere Sponsors can conduct their studies year-round
by taking advantage of Australia’s counter-flu and allergy seasons
Avance
Clinical has more than 20-years of experience and is now one of Australia’s
leading Contract Research Organisations. Avance Clinical facilitates quality
drug development by aligning people, skills, and expertise in the pursuit of
drug development for a healthier world.
Avance
Clinical is committed to providing high-quality clinical research services with
its highly experienced team.
The
collective pool of knowledge and experience at Avance Clinical continually
grows through the careful selection of experts who also demonstrate passion in
their chosen field.
Avance
Clinical offers high quality services in an established clinical trial ecosystem,
that includes world-class Investigators and Sites able to access specialised
patient groups. Other benefits include:
Access to independent
Phase 1 facilities across Australia including hospital-based units for
critical care
Dedicated
Investigators committed to clinical research
Major hospitals
with world class infrastructures and dedicated Clinical Trial Units